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Abstract: 
Background: Pregnancy is associated with various forms of thrombotic microangiopathy, 
including the hemolytic uremic syndrome. A previous small French study suggested that 
pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of 
atypical HUS linked to complement alternative pathway  dysregulation.  
Design, setting, participants and measurements: We sought to retrospectively analyze the 
presentation, outcome, and frequency of complement alternative pathway genes variants in a 
larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-
associated hemolytic uremic syndrome.   
Results: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were 
included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and 
in the post-partum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six 
(78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions and 4 (5%) 
received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients 
reached end-stage renal disease, 15 (19%) had chronic kidney disease and 18 (28%) patients 
experienced hemolytic uremic syndrome relapse.. Twenty four patients (27%) received a renal 
transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) cases. 
Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) 
and CFI genes (9%).  
Conclusions: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic 
uremic syndrome non-related to pregnancy have the same severity at onset and during follow-
up and the same frequency of complement gene variants.  
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Introduction 
Hemolytic and uremic syndrome (HUS) is a rare and severe form of thrombotic 
microangiopathy  associated with a poor renal prognosis. It is characterized by the association 
of mechanical hemolytic anemia, thrombocytopenia and renal failure1. HUS arises from an 
insult to endothelial cells  that in turn may result from distinct pathogenic mechanisms: 
verotoxin-induced endothelial cells activation and apoptosis in Shiga toxin-induced HUS , 
acquired or constitutional complement alternative pathway dysregulation leading to 
complement-induced endothelial cells damage in atypical HUS or various, more or less well-
defined, patterns of endothelial cells lesions in the heterogeneous group of secondary HUS 
associated with autoimmune diseases, drugs, infections and pregnancy. Pregnancy carries a 
high risk for various forms of thrombotic microangiopathy, including ADAMTS13-deficiency 
associated thrombotic thrombocytopenic purpura2 but also HUS3. The diagnosis of pregnancy 
associated-HUS  can be difficult with   preeclampsia, HELLP syndrome and in some 
instances severe post-partum hemorrhage presenting with similar features4,5. Moreover, until 
few years ago, pregnancy associated-HUS was included in the group of secondary forms of 
thrombotic microangiopathy. 
 The identification of complement alternative pathway dysregulation as a major risk 
factor for atypical HUS6,7 has led several authors to reconsider the pathogenesis of secondary 
forms of HUS and to assess whether in these settings complement alternative pathway 
dysregulation combined with specific precipitating events could lead to thrombotic 
microangiopathy. Previously, we tested this hypothesis in a small series of pregnancy-
associated HUS and showed that 86% of patients with mainly post-partum HUS harbored 
complement genes variants and had an initial presentation and outcome similar to non-
pregnancy related atypical HUS3. This first study was rather limited as it included only 21 
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patients from a single country. Thus, there remained some uncertainties and controversies 
regarding the pathogenesis and consequently the treatment of pregnancy-associated HUS, a 
crucial question since the clinical availability of the first complement inhibitor, eculizumab4. 
We sought to analyze the presentation, outcome, and frequency of complement alternative 
pathway genes variants in a large international cohort of patients presenting with pregnancy-
associated HUS.  
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Methods and Methods 
Patients 
This was a retrospective multicentric study conducted in France, the United Kingdom and 
Italy, three countries in which a HUS registry has been established. We identified through 
computerized databases all women with pregnancy-related HUS included in these registries 
between 1983 and 2013 and for whom complement workup has been performed in the three 
national reference centers (Department of Biological Immunology at Hôpital Européen 
Georges Pompidou, Paris, France; Mario Negri Institute, Bergamo, Italy, and The UK 
National aHUS service in Newcastle). 
Definitions 
All patients with a diagnosis of pregnancy-associated HUS from the three registries were 
included in the study. Pregnancy-associated HUS was defined as a HUS occurring during 
pregnancy, or in the post-partum period (up to 12 weeks after delivery). HUS was defined by 
the association of at least three of the following criteria: mechanical hemolytic anemia 
(hemoglobin < 10g/dl, Lactate dehydrogenase > upper limit of normal, undetectable 
haptoglobin, presence of schistocytes), thrombocytopenia (platelets count < 150 x 103/L), 
acute kidney injury (serum creatinine > 1.1 mg/dLl or > 25% increase from baseline value) or 
typical features of thrombotic microangiopathy in a kidney biopsy (fibrin/platelet thrombi, 
endothelial cells swelling and detachment from the basement membrane, double contours). 
Patients with pre-eclampsia (defined by hypertension > 140/80 mmHg and proteinuria > 300 
mg/day8 after 20 weeks of gestation) prior to the development of thrombotic microangiopathy 
features, HELLP (Hemolysis, Elevated Liver enzymes and Low Platelet count) syndrome 
(defined by aminotransferase > 70 U/L, Lactate dehydrogenase > 600 U/L and platelet count 
< 100 x 103/L)9, massive post-partum bleeding or other identified causes of secondary HUS 
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(lupus, antiphospholipid syndrome) were excluded. Chronic kidney disease was defined by a 
glomerular filtration rate estimated using the Modification of Diet in Renal Diseases formula 
< 60 ml/min/1.73m2. 
Medical records of included patients were reviewed and relevant clinical and biological 
features were collected.  
Complement analysis 
Complement evaluation and genetic analysis were performed in each reference center in the 
usual management of the patients. Plasma concentrations of C3, C4, factor B , factor F and I  
and membrane cofactor protein expression on granulocytes were measured according to local 
practice6,7,10,11. All coding sequences for complement factor H , complement factor I, 
membrane cofactor protein , C3, factor B and thrombomodulin genes were sequenced as 
described previously6,7,11. Variants were categorized as: a) Pathogenic: novel (not found in the 
general population) or rare (minor allele frequency in the general population  <0.1%) variant 
reported to cause disease in literature; functional data indicating the variant affects protein 
function or expression. b) Likely pathogenic: novel or rare variants that change protein 
sequence or affect splicing and with highly deleterious effects by in silico predictions but 
without functional data; found in disease-related functional domains;  c) Uncertain 
significance: novel or rare variants that change protein sequence or affect splicing with no 
available functional data; uncertain deleterious effects by in silico prediction12. 
All patients gave informed consent for genetic analysis according to the Declaration of 
Helsinki. 
Statistical analysis 
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Data are presented as percentages or means (± standard deviation). The Wilcoxon test was 
performed for quantitative variables, and Fischer’s exact test for qualitative data. All analyses 
with p value <0.05 were considered statistically significant. 
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Results 
Eighty-seven patients who presented with pregnancy-associated HUS between 1983 and 2013 
were included in the study. The distribution by country and decade is presented in 
supplementary table S1. Pregnancy-associated HUS represented 16% (87/547) of HUS cases 
occurring in females aged 18-45 years reported in the three national registries. The main 
characteristics of these patients are summarized in Table 1.  
Patients’ characteristics at presentation. 
Mean age at the time of pregnancy-associated HUS was 29 ± 6 years (Table 1). Fourteen 
patients (16%) had a familial history (at least one affected family member) of atypical HUS. 
Seven (8%) patients had a personal history of atypical HUS and had experienced one (n=6) or 
several (4 in one patient) episodes of atypical HUS not related to pregnancy before presenting 
with pregnancy-associated HUS. One patient had a documented complement gene variant 
(complement factor H) prior to pregnancy. Five patients had previously underwent  plasma 
exchanges for atypical HUS, and two had a stage 3 chronic kidney disease related to atypical 
HUS. The risk for HUS occurrence was similar for the first pregnancy (48/82, 58%) and for 
subsequent (2nd pregnancy) pregnancies (42%). HUS occurred mainly in the post-partum 
period (n=63, 76%; mean time of 14 ± 12 days after delivery) (Figure 1), regardless of the 
rank of pregnancy. Twenty patients (24%) presented with HUS during pregnancy, mostly 
(n=18, 77%) in the third trimester.  Acute kidney injury was severe with 56 (71%) patients 
requiring dialysis at presentation. In contrast thrombocytopenia was mild (mean platelet count 
97 x103/L ± 99) and even absent in 13 (15%) patients. All patients had aminotransferases 
levels < 70 U/L and ADAMTS13 activity > 10%. Extra-renal manifestations were noted in 11 
patients (14%). Kidney biopsy performed in 8 patients (mostly with normal platelet count) 
disclosed typical features of thrombotic microangiopathy. 
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Treatment 
Fifty-six patients (56/72, 78%) underwent plasma exchanges as first-line therapy, 21 (21/51, 
41%) received plasma infusions and sixteen (16/60, 27%) corticosteroids (Table 1). 
Eculizumab was used in 4 cases starting 2011, as a second-line therapy after plasma 
exchanges. Three patients had HUS in the post-partum, one during pregnancy but eculizumab 
was started after delivery in all cases. The four patients had severe acute kidney injury 
requiring dialysis but no extra-renal manifestations and received eculizumab 4 days, 5 days, 1 
month and 2 months after HUS diagnosis.  Three of them had complement gene variants (an 
isolated complement factor H variant (n=2) and combined complement factor H/complement 
factor I variants (n=1)). 
Outcome. 
Short-term outcome 
No maternal death was reported. Fetal or neonatal death occurred in 11 (14%) cases (Table 2). 
Twenty-five patients (32%) reached end-stage renal disease within three months of first 
manifestations of pregnancy-associated HUS and 15 (19%) developed chronic kidney disease. 
The risk of end-stage renal disease (29/56 (51%) vs (7/16) 47% p= 0.77) and chronic kidney 
disease (11/56 (20%) vs 3/16 (20%), p= 1) did not differ between patients treated with plasma 
exchanges and those who did not undergo plasma exchanges. Among the four patients treated 
with eculizumab, three (two with complement genes variants, one without) had a complete 
recovery of renal function. The remaining patient treated with eculizumab two months after 
diagnosis remained dialysis-dependent.  
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Long-term outcome 
Eight patients out of the 62 (13%) who did not reach end-stage renal disease within 3 months 
of pregnancy-associated HUS had an HUS relapse: in the post-partum of a subsequent 
pregnancy (n=1), in the setting of malignant hypertension (n=1) or an infectious illness (n=1), 
or without any identified triggering event (n=5). In 6 (75%) relapsing patients, HUS relapse 
led to end-stage renal disease. At last follow-up (7.2 years ± 5.2), 22/78 (28%) patients had an 
estimated glomerular filtration rate > 60 ml/min/1.73 m2, 15 (19%) had chronic kidney 
disease and 41 (53%) had progressed to end-stage renal disease. Twenty four patients (24/87, 
27%) received a renal transplantation and a recurrence of HUS occurred in 10 patients (10/24, 
42%). Overall, eighteen patients (18/87, 21%) experienced HUS relapse either in their native 
kidneys or in a renal graft. 
 
Complement work up 
Available results for complement component assays and complement genes sequencing are 
presented in tables 3 and 4. C3 serum level was low in 29/74 (39%) of patients. Twenty-three 
women among the 29 (79%) with low serum C3 level had complement genes variants. Novel 
or rare variants in complement genes (missense, nonsense variants, ins-del and exon-intron 
boundary variants affecting splicing) were detected in 49/87 (56%) patients, most frequently 
in the complement factor H (n=26, 30%) and complement factor I genes (n=8, 9%). Eight 
patients (9%) presented combined variants: complement factor H and complement factor I 
variants (n=2), complement factor H and membrane cofactor protein (n=2), complement 
factor H and C3 (n=2), complement factor I and membrane cofactor protein (n=1) or 
complement factor H and thrombomodulin (n=1). One patient had two heterozygous variants 
in complement factor I gene. Thirty-eight patients (44%) had no detected variant in 
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complement genes. Detailed description of the 59 variants detected in complement genes are 
shown in table 4. Based on published functional data, low protein level and/or high 
pathogenicity predicted by in silico analysis, 40 variants were considered to be pathogenic, 
the remaining 19 variants being of uncertain significance.  
 
Patients’ characteristics and outcome depending on the presence or absence of 
complement genes variants. 
Frequency of complement genes variants in patients presenting with HUS during their first 
pregnancy and in those presenting with HUS during subsequent ( 2nd) pregnancies did not 
significantly differ (23/48 (47%) vs 23/35 (65%), p = 0.11) (Figure 1). Patients with 
complement genes variants required dialysis at presentation more frequently than those with 
no detected variant (35/89 (81%) vs 21/38 (58%), p=0.02). The frequency of neurological 
involvement was similar in patients with or without complement genes variants (5/49 (12%) 
vs 2/38 (6%), p=0.38) (table 5). The long-term outcome of HUS was more severe in patients 
with documented complement gene variants compared to patients with no identified variant 
(table 5). Patients with variants progressed to end-stage renal disease more frequently than 
patients with no variant detected (29/49 (64%) vs 12/38 (36%), p = 0.01). The risk of relapse 
was also significantly greater in patients with variants compared to those without (13/49 
(38%) vs 5/38 (16%), p =0.04). Among patients with mutations, there was no difference 
according to the type of genetic abnormality (supplementary table S2).  
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Patients’ characteristics and outcome depending on the timing of HUS (during 
pregnancy or in the post-partum). 
Compared to patients with HUS in the post-partum, patients presenting with HUS during 
pregnancy had more frequently a personal history of chronic kidney disease or HUS (25% vs 
5%, p= 0.02) and tended to require less frequently dialysis in the acute phase (56% vs 76%, p 
=0.08) even though this difference was not statistically significant (table 6). However, the 
frequency of complement genes variants and the risk of HUS relapse, chronic kidney disease 
and end-stage renal disease did not differ between the two groups. 
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Discussion 
 This is the largest to date cohort study assessing the presentation, the outcome and the 
frequency of complement genes variants in pregnancy-associated HUS. It was performed 
using three distinct registries in three national reference centers for HUS. Cases were 
diagnosed over a rather long period of time spanning over four decades, but until the very 
recent availability of eculizumab the care of HUS did not significantly vary.  
 The results indicate that pregnancy-associated HUS has a severity at onset (2/3 of 
patients requiring dialysis) and in the long-term (more than half of the patients reaching end-
stage renal disease), and a frequency (56%) and distribution of complement genes variants 
similar to those of atypical HUS cases from the same three national registries6,7,13. Pregnancy-
associated HUS is thus an atypical HUS triggered by pregnancy, in keeping with the findings 
of a previous small study performed in one country3. It remains unknown why a significant 
proportion of women presented with HUS in the second or subsequent pregnancies and not in 
earlier pregnancies and overall the precise mechanism by which pregnancy precipitates HUS 
remains ill-defined. During normal pregnancy, complement activation occurs in the placenta 
at the interface between the mother and the fetus14 and one would expect pregnancy-
associated HUS to occur mainly during pregnancy. Nevertheless, complement alternative 
pathway regulation in the placenta depends predominantly on CD59 and decay accelerating 
factor 15,16, two membrane-bound proteins that negatively control complement alternative 
pathway. Neither CD59 nor Decay Accelerating Factor has been to date implicated in the 
pathogenesis of atypical HUS and their overexpression in the placenta may compensate for 
the deficiency in other regulatory proteins implicated in the pathogenesis of atypical HUS. In 
contrast, during the post-partum, the protection conferred by the overexpression of Decay 
Accelerating Factor and CD59 is lost with placental delivery. Post-partum bleeding and 
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infection may also trigger excessive complement activation in predisposed women and 
ultimately lead to HUS.  
 Three-quarters of the cases included in the present study occurred in the post-partum 
of uneventful pregnancies and in this setting the diagnosis of HUS is rather straightforward. 
For the remaining one-quarter of cases occurring during pregnancy (mainly during the third 
trimester) the differential diagnosis is more complex as several disorders may mimic HUS, 
including preeclampsia, HELLP syndrome or severe bleeding4. We have carefully excluded 
patients with these complications of pregnancy from the study. Besides, one-quarter of 
patients with HUS during pregnancy had a history of chronic kidney disease/HUS and the 
existence of renal vascular damage prior to gestation may explain the occurrence of HUS 
early during pregnancy and before delivery.  Furthermore, patients with HUS during 
pregnancy and those with HUS in the post-partum had a similar high frequency (50.0%-59%) 
of complement genes mutations. In contrast, only a minority (8-10%) of patients with 
preeclampsia and HELLP syndrome harbor complement genes variants, mostly of unknown 
significance or non-pathogenic17. Finally, patients with HUS during pregnancy and those with 
HUS in the post-partum shared the same severe renal outcome (risk of end-stage renal disease 
of 44%-55%), in a sharp contrast to the usual complete renal recovery in preeclampsia and 
HELLP syndrome patients. Thus, the present cohort reflects the presentation, genetic risk 
factors and outcome of HUS occurring during pregnancy or in the post-partum. 
 Two-thirds of complement genes variants detected in patients with pregnancy-
associated HUS were considered to be pathogenic, based on quantitative defects and proven 
or predicted functional abnormalities of the encoded protein. These findings are similar to 
those of complement genes variants detected in atypical HUS12. The presence of an identified 
complement gene variant was associated with a more severe outcome of pregnancy-associated 
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HUS with an increased risk of HUS relapse and of progression to end-stage renal disease.  
However, there was no difference in terms of presentation and outcome between patients with 
different types of complement genes mutations.   
 The present study raises several issues regarding the management of pregnancy-
associated HUS. Firstly, plasma exchanges did not improve the renal outcome of pregnancy-
associated HUS, and the risk of end-stage renal disease remained similarly high (around 50%) 
in patients who underwent plasma exchanges and in those who did not.  Secondly, the 
availability of the anti-C5 antibody eculizumab has dramatically changed the treatment and 
outcome of atypical HUS18,19. However, pregnant women were excluded from prospective 
trials with eculizumab and no specific data were reported for the few patients with post-
partum HUS. In the present series only four patients with pregnancy-associated HUS received 
eculizumab and a limited number of cases reports of the use of the drug in this setting are 
available in the literature20-23. In all these cases except one, eculizumab proved efficacious in 
controlling HUS and improving renal function. Based on the experience with the eculizumab 
in patients with paroxysmal nocturnal hemoglobinuria24, the use of eculizumab during 
gestation seems safe, even though the drug was detected in one-third of cord blood samples 
but was not present in maternal breast-milk. Careful monitoring of complement blockade  is 
mandatory as pregnancy may require an increase in the dosage and/or the frequency of 
eculizumab infusions due to the increase in the distribution volume or C5 synthesis25. Based 
on all these available data, treatment of P-HUS should be similar to the treatment of non-
pregnancy-related atypical HUS, and relies on eculizumab use, as first-line treatment if the 
clinical presentation (post-partum of an uneventful pregnancy) and/or personal or familial 
history is highly suggestive of HUS or as second-line treatment after plasma exchange if a 
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diagnostic work-up is necessary. Nevertheless, a further specific assessment of eculizumab 
use in pregnant women with HUS is warranted. 
 Secondly, the present data will help clinicians counsel patients with a history of 
atypical HUS or healthy carriers of complement genes variants who wish to start a pregnancy. 
In our study the risk of HUS was the highest during the first pregnancy, but remained 
relatively high during subsequent pregnancies and may even increase as eculizumab rescues 
patients from end-stage renal disease and thus preserves their ability to conduct a pregnancy. 
However, the availability of eculizumab has dramatically improved the outcome of atypical 
HUS and nowadays most clinicians do not advise against pregnancy in a patient with a history 
of atypical HUS or a healthy carrier of complement gene variant. Patients should make their 
decision about pregnancy after being informed of the risk of atypical HUS relapse (estimated 
however based mainly on studies in atypical HUS non-related to pregnancies) but also of the 
risks inherent to potential clinical or subclinical chronic renal damage due to previous 
episodes of atypical HUS, including hypertensive complications of pregnancy that may occur 
despite treatment of eculizumab25. Pregnancy in these patients requires close collaborative 
monitoring by nephrologists and obstetricians in level III maternity hospitals, starting in the 
first weeks of pregnancy and up to three months after delivery, in order to rapidly detect and 
thus treat the early manifestations of HUS. 
 In conclusion, pregnancy-related atypical HUS is a very severe disease, with a poor 
prognosis for maternal renal function if left without specific efficacious treatment. It is 
associated with variants in complement genes in 56% of patients, and pregnancy seems an 
important trigger for the disease in these at-risk patients.  Prospective studies are needed in 
order to specifically assess the efficacy and safety of eculizumab in pregnancy-associated 
HUS.   
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 Number (%) / mean ± SD 
Number of patients 87 
Age at HUS onset (years) 29 ± 6.0 
Number of previous pregnancies 0.7 ± 1.2 
Rank of pregnancy HUS was diagnosed in (n=83) 
    1st 
    2nd 
    3rd 
   ≥ 4th 
 
48 (58%) 
23 (28%) 
5 (6%) 
7 (8%) 
Pre-eclampsia during previous pregnancies (n=53) 5 (9%) 
Fetal loss during previous pregnancies (n=49) 10 (20%) 
Familial history of atypical HUS 
Personal history of atypical HUS 
14 (16%) 
7 (8%) 
Timing of HUS* 
    Post-partum 
    During pregnancy 
 
63 (76%) 
20 (24%) 
Features at hemolytic and uremic syndrome onset 
    Serum creatinine (mg/dL)  
    Dialysis 
    Platelet count x103(/L)  
    Hemoglobin (g/dL)  (n=66) 
    Lactate dehydrogenase (U/L) (n=56) 
    Neurological involvement 
    Other extra-renal manifestations** 
 
6.1 ± 5.2 
56 (71%) 
97 ± 99  
7.8 ± 1.9 
2225 ± 1617 
7 (9%) 
4 (6%) 
Treatment 
    Number of patients who underwent plasma exchange (n=72)  
   Number of plasma exchange sessions performed per patient (n=41) 
  Number of patients who received plasma infusion (n=51) 
  Number of patients who received eculizumab 
 
56 (78%)  
13 ± 10 
21 (41%) 
4 (5%) 
22 
 
 
    Steroids (n=60) 
   Other *** 
16 (27%) 
3 (5%) 
Table 1: Characteristics of 87 patients with pregnancy-associated hemolytic uremic syndrome .  
* Timing of HUS is unknown for four patients. 
**pulmonary edema (n=2), pulmonary embolism (n=1). 
*** Intravenous immunoglobulins (n=2), rituximab (n=1). 
The numbers of patients for whom data are available are reported in brackets 
SD, standard deviation.  
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 Number (%) / mean ± SD 
Duration of follow-up (years) (n=78) 
Patients who reached end-stage renal disease*  
   End-stage renal disease within 3 months of pregnancy-HUS (n=78) 
7.2 ± 5.2 
41 (53%) 
25 (32%) 
  
Patients with an estimated GFR <60 mL/min/1.73m2 without end-stage 
renal disease 
15 (19%) 
Patients with an hemolytic and uremic syndrome relapse  
    Relapse in the native kidneys  
      Number of relapses 
      Patients reaching end-stage renal disease after a relapse 
18 (28%) 
8/62* (13%) 
1.6 ± 1.4 
6/8 (75%) 
    Relapse in the renal graft 10/24 (42%) 
  
 
Table 2: Outcome of 87 patients with pregnancy-associated hemolytic uremic syndrome. 
Abbreviations: SD, standarddeviation. eGFR, glomerular filtration rate estimated using the MDRD formula..  
* Nine patients progressed to end-stage renal disease during follow-up without overt hemolytic and uremic 
syndrome relapse. The timing of end-stage renal disease is unknown in 2 patients.**, number of patients who did 
not reach end-stage renal disease within 3 months of pregnancy-associated HUS onset.   
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Number (%) 
 
Complement components assays  
  Low serum C3 
 
29/74 (39%)* 
  Low serum CFH 
 
8/54 (15%)** 
  Low serum FI 
 
5/43 (12%)*** 
  Low serum FB 
 
0/45 (0%) 
  Low MCP expression on granulocytes 
 
6/39 (15%)**** 
Complement and THBD genes sequencing (n=87) 
 
 
  Number of patients with a variant detected 49 (56%) 
  Isolated CFH variant 26 (31%) 
  Isolated CFI variant 8 (9%) 
  Isolated MCP variant 3 (3%) 
  Isolated C3 variant 3 (3%) 
  Isolated FB variant 0 (0%)  
  Isolated THBD variant 1 (1%) 
  Combined mutations 8 (9%) 
 
  No variant detected 
 
38 (44%) 
 
 
Table 3: Results of complement components assays and complement genes sequencing in 
patients with pregnancy-associated hemolytic uremic syndrome. 
Abbreviations: CFH, complement factor H. CFI, complement factor I. MCP, membrane cofactor protein. 
FB, factor B. THBD, thrombomodulin. 
 
*60% of patients with CFH or C3 variants had low serum C3 level.  
**32% of patients with CFH variant had low serum CFH level. 
***44% of patients with CFI variants had low serum CFI level. 
****100% of patients with MCP variants had low MCP expression on granulocytes. 
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Patient Gene Variation 
Classification 
 
Animo acid change* Population 
frequency** 
Protein Level Protein 
Function 
References 
1 CFH Pathogenic p. Arg1215Gly novel ↔ ↓ 26,27 
2 C3 Pathogenic p.Arg592Gln 0.000008241 ↔ ↓ 28 
3 MCP Pathogenic p.Met44Leu 0.0004454 ↓ N/A  
4 CFH Pathogenic p.Arg1210C 0.0001730 ↔ ↓ 26,27,29 
5 CFH Pathogenic p.Thr645ArgfsX20 novel ↓ N/A  
6 CFH Pathogenic p.Trp71* novel ↓ N/A  
7 CFH Pathogenic c.3468dupA novel ↓ N/A 30 
 CFI VUS Pro553Ser 0.000008243 ↔ N/A 10,31 
8 CFH Pathogenic p.Ser1191Leu novel ↔ ↓ 26,32 
9 CFH Pathogenic p.Val1197Ala novel ↔ ↓ 29,32,33 
10 CFH Pathogenic p.Arg1215X  ↔ N/A  
11 CFH Pathogenic CFH/CFHR3 hybrid novel ↔ ↓ 34 
12 CFH Pathogenic c.3486delA  ↓ N/A  
13 CFI Pathogenic p.W145X novel ↓ N/A 35 
14 CFI Pathogenic p.Ile416Leu 0.001113 ↓ N/A 6,10,36,37 
15 CFI VUS p.Ile578Thr 0.00002477 ↔ N/A 10 
16 CFH Pathogenic p.G1194D 0.00003295 N/A N/A 38 
 MCP Pathogenic p.F242C novel ↓ N/A 39,40 
17 CFI Pathogenic p.A240G 0.0002720 ↓ N/A 7,31,36 
18 CFH VUS p.P279L novel N/A N/A  
19 THBD VUS p.D163N novel N/A N/A  
20 CFH Pathogenic K474Nfs6X     
21 MCP Pathogenic IVS2+2T>G 0.00003311 ↓ N/A 41 
 MCP Pathogenic p.Y189D novel ↓ N/A 41 
 CFI VUS p.D44N 0.00001648    
22 CFI VUS p.D519N 0.00001658 ↔ ↓ 42 
23 CFH VUS p.N516K 0.0004046    
24 CFH Pathogenic p.R78G novel ↔ ↓ 38,43 
25 CFH VUS p.R303Q 0.00001650    
26 C3 Pathogenic p.Arg161Trp 0.000008240 ↔ ↓ 6,44 
27 C3 VUS p.Ile1095Ser novel NA NA 6 
28 CFH Pathogenic p.Arg53Cys 0.00001652 ↔ ↓ 45 
29 CFH Pathogenic p.Ala161Ser 0.00004124 N/A N/A  
30 CFH Pathogenic p.Gly397Arg novel N/A N/A  
31 CFH Pathogenic p.Cys431Tyr 0.000008262 N/A N/A  
32 CFH Pathogenic p.His893Arg novel N/A N/A  
33 CFH Pathogenic p.Val1197Ala (Hom) novel ↔ ↓ 29,32,46 
34 CFH Pathogenic p.Val1197Ala novel ↔ ↓ 13-15,18,19 
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35 CFH Pathogenic p.Arg1210Cys 0.0001730 ↔ ↓ 26,27,29,47,48 
 
 MCP Pathogenic p.Tyr29Stop novel ↓ N/A  
 
36 
 
CFH 
 
Pathogenic 
 
p.Gln81Pro 
 
novel 
N/A N/A  
37 CFH  VUS p.Lys1186Thr novel N/A N/A  
 CFI VUS p.Ile340Thr 0.00004120 ↔ ↓ 42 
38 C3 Pathogenic p.Lys155Gln 0.003362 N/A N/A  
 CFH Pathogenic p.Lys584Stop novel N/A N/A  
39 C3 Pathogenic p.Arg161Trp 0.000008240 ↔ ↓ 6,44 
 CFH VUS p.Arg341His 0.00001653 N/A N/A  
40 CFH Pathogenic p.Cys864Ser novel N/A N/A  
 THBD Pathogenic p.Ala43Thr 0.003430 N/A N/A  
41 CFI Pathogenic p.Arg474Stop 0.00004956 ↓ N/A 6,36,49 
42 CFI Pathogenic p.Gly119Arg 0.0005290 ↓ N/A 6,31,36 
43 CFH Pathogenic p.Gly218Glu novel ↓ N/A 6,7 
44 CFI Pathogenic p.Gly119Arg 0.0005290 ↓ N/A 6,31,36 
 CFI VUS p.Gly424Asp novel ↔ N/A 36 
45 MCP Pathogenic IVS3+2T>G 0.00003121 N/A N/A  
46 MCP Pathogenic p.Tyr248Stop novel ↓ N/A  
47 CFH VUS p.Lys82Arg; 0.00001649 N/A N/A  
48 CFH Pathogenic p.Tyr1016* (Hom) 0.000008239 ↓ N/A  
49 CFH Pathogenic p.Arg161Trp 0.000008240 ↔ ↓ 6,44,50 
 
Table 4: Characteristics of complement genes variants identified in patients with pregnancy-
associated hemolytic uremic syndrome. 
Abbreviations: CFH, complement factor H. CFI, complement factor I. MCP, membrane cofactor protein. 
FB, factor B. THBD, thrombomodulin. VUS, variant of undetermined significance.  ↔, unchanged. ↓, 
decreased. * all heterozygous unless specified. **, from the Exome Aggregation Consortium (ExAc) 
database (http://exac.broadinstitute.org/). 
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 Complement gene 
variant detected 
(n=49) 
 
No complement gene 
variant detected  
(n=38) 
p 
At presentation    
    Age (years) 27.8 ± 6.0 30.4 ± 5.8 0.06 
    Personal history of HUS 4 (8%) 3 (9%) 1 
    
    Onset in the post-partum 39 (79%) 28 (72%) 0.49 
    Need for dialysis 35 (81%) 21 (58%) 0.02 
    Neurological involvement 5 (12%) 2 (6%) 0.38 
    Plasma exchange 30 (79%) 26 (77%) 0.80 
 
During follow-up (n= 74)   
 
    Duration of follow-up (years) 6.2 ± 3.6 6.7 ± 4.1 0.75 
    Relapse 13 (38%) 5 (16%) 0.04 
   Chronic kidney disease  9 (21%) 6 (18%) 0.81 
   End stage renal disease. 29 (64%) 12 (36%) 0.01 
 
Table 5: Main characteristics of 87 patients with pregnancy-associated hemolytic uremic 
syndrome patients with (n=49) or without complement gene variants (n=38). 
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 HUS during pregnancy 
(n=20) 
 
HUS in the post-partum 
(n=63) 
 
p 
 
Medical history    
Personal history of HUS 
 
4 (20%) 3 (5%) 0.03 
At onset    
     Age (years) 28.5 ± 5  29.2 ± 6 0.68 
     Need for dialysis 10 (56%) 45 (76%)    0.08 
     Neurological involvement 0 (0%) 7 (12%) 0.12 
    Plasma exchange 10 (59%) 44 (83%) 0.04 
 
Complement genes variants detected 10 (56%) 28 (78%) 
 
0.09 
 
Outcome 
   
    Duration of follow-up (years) 6.9 ± 3.2 7.1 ± 5.1 0.80 
    HUS relapse 4 (20%) 14 (30%) 0.33 
   Chronic kidney disease               4 (22%) 11 (19%) 0.79 
   End stage renal disease 8 (44%) 32 (55%) 0.59 
 
Table 6: Main characteristics of 83 patients who presented with hemolytic uremic syndrome 
during pregnancy (n=20) or in the post-partum (n=63). 
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Legend to Figures:  
Figure 1: Rank of pregnancy and timing of pregnancy-associated hemolytic uremic 
syndrome in 72 patients for whom the precise data are available.  
 
